Injectable Treatments in Dermatology: Botox, Fillers, and Oversight

Injectable treatments occupy a significant and regulated segment of dermatologic practice, encompassing both cosmetic applications and medically indicated uses. This page covers the major categories of injectables used in dermatology — neurotoxins and dermal fillers — their mechanisms, clinical contexts, and the federal and state oversight frameworks that govern their use. Understanding the distinction between these product classes, and the credentials required to administer them, is essential for anyone navigating dermatology care in the United States.

Definition and Scope

Injectable treatments in dermatology fall into two primary regulatory and functional categories: botulinum toxin products (commonly referred to as Botox, a brand name) and dermal fillers. Both categories are regulated by the U.S. Food and Drug Administration (FDA) as medical devices or biological products, depending on formulation, under the Federal Food, Drug, and Cosmetic Act.

Botulinum toxin products are FDA-approved biological drugs. The FDA has approved four distinct botulinum toxin type A formulations for dermatologic and aesthetic use: onabotulinumtoxinA (Botox/Botox Cosmetic), abobotulinumtoxinA (Dysport), incobotulinumtoxinA (Xeomin), and prabotulinumtoxinA (Jeuveau). A fifth product, rimabotulinumtoxinB (Myobloc), is a type B toxin approved for cervical dystonia but used off-label in some contexts (FDA, Approved Botulinum Toxin Products).

Dermal fillers are classified by the FDA as medical devices under 21 CFR Part 880. The FDA recognizes distinct filler material classes, including hyaluronic acid (HA) fillers, calcium hydroxylapatite (CaHA), poly-L-lactic acid (PLLA), and polymethylmethacrylate (PMMA) microspheres. Each class carries a different duration of effect and a distinct adverse event profile.

The scope of injectable use extends beyond cosmetic enhancement. Botulinum toxin holds FDA approval for hyperhidrosis (excessive sweating), chronic migraine, and certain muscle spasticity conditions — indications that place it squarely within medical dermatology. The broader regulatory context for dermatology shapes how these products are approved, labeled, and monitored post-market.

How It Works

Neurotoxin mechanism: Botulinum toxin inhibits the release of acetylcholine at the neuromuscular junction by cleaving SNARE proteins required for vesicle fusion. The result is temporary, dose-dependent flaccid paralysis of targeted muscle groups. Onset occurs within 24–72 hours of injection, with full effect typically observed at 2 weeks. Duration ranges from 3 to 6 months depending on formulation, injection site, muscle mass, and individual patient metabolism (FDA Prescribing Information, Botox Cosmetic).

Dermal filler mechanism: Fillers work through volume replacement rather than muscle inhibition. Hyaluronic acid fillers attract and bind water molecules, physically occupying subcutaneous or intradermal space. CaHA fillers provide immediate volume while stimulating collagen synthesis over subsequent months. PLLA stimulates a fibroblast response, producing gradual volumization over 6 to 12 weeks with effects lasting up to 2 years. PMMA fillers are the only permanent option currently FDA-approved; their non-biodegradable microspheres remain at the injection site indefinitely.

The depth of injection is a critical technical variable:

1. Intradermal injection — targets fine lines and superficial skin depressions
2. Subdermal injection — addresses mid-face volume loss and lip augmentation
3. Supraperiosteal injection — used for structural support near bone, such as chin or jawline definition
4. Intramuscular injection — the route for all botulinum toxin applications

Incorrect injection depth is the leading technical cause of adverse outcomes, including vascular occlusion, a rare but sight-threatening complication when filler is inadvertently introduced into arterial supply. The FDA issued a safety communication in 2021 specifically addressing the risk of blindness and stroke associated with facial filler injection near ocular vessels (FDA Safety Communication on Dermal Fillers, 2021).

Common Scenarios

Injectable treatments appear across a spectrum of dermatologic presentations, both cosmetic and functional:

• Dynamic facial rhytids (wrinkle lines): Botulinum toxin targeting the frontalis, corrugator supercilii, and orbicularis oculi muscles represents the highest-volume cosmetic injectable procedure in the United States. The American Society of Plastic Surgeons reported over 7.4 million botulinum toxin procedures performed in the U.S. in 2018 (ASPS 2018 Statistics).
• Primary axillary hyperhidrosis: OnabotulinumtoxinA holds an FDA approval specifically for this indication, with clinical trials demonstrating a 4-week onset of anhidrosis lasting approximately 7 months per treatment cycle.
• Mid-face volume loss: HA fillers are the dominant choice for nasolabial folds, tear troughs, and lip augmentation due to reversibility via hyaluronidase injection.
• Acne scarring: Subcision combined with HA filler placement addresses rolling acne scars by releasing fibrous tethering and restoring subdermal volume. This overlaps with the scope covered under scar treatment and management.
• Lip augmentation: HA fillers are the standard of care; volumes typically range from 0.5 mL to 1.0 mL per session.

Decision Boundaries

The decision to use injectables, and the choice between product classes, involves regulatory, clinical, and credential-based boundaries.

Botulinum toxin vs. filler — core distinctions:

Credential and oversight boundaries: Botulinum toxin products require a prescription, meaning their administration must be ordered and supervised by a licensed prescriber. The FDA does not independently regulate who may inject fillers at the practitioner level; this authority rests with individual state medical and nursing boards. State regulations vary substantially — 12 states permit registered nurses to administer fillers under physician supervision, while other states restrict injections to physicians, physician assistants, or advanced practice nurses with specific training documentation (National Conference of State Legislatures, State Scope of Practice Laws).

Off-label use: A substantial portion of filler applications, including tear trough injection and hand rejuvenation, occur off-label. The FDA permits licensed practitioners to use approved products off-label, but the prescribing clinician assumes full liability for outcomes outside labeled indications.

Contraindication thresholds: Absolute contraindications to botulinum toxin include known hypersensitivity to any toxin formulation and active infection at the injection site. Relative contraindications include neuromuscular junction disorders such as myasthenia gravis and Lambert-Eaton syndrome, given the risk of potentiated weakness. Filler contraindications include active autoimmune conditions affecting connective tissue and known allergy to filler constituents. The distinction between cosmetic and medically indicated injectable use is explored further under cosmetic vs. medical dermatology.

References

• FDA: Botox, Botox Cosmetic (OnabotulinumtoxinA) Information
• FDA: Dermal Fillers (Soft Tissue Fillers)
• FDA Safety Communication: Update on Safety Concern – Hyaluronic Acid Dermal Fillers (2021)
• FDA Prescribing Information: Botox Cosmetic (2017)
• 21 CFR Part 880 — Medical Devices (Electronic Code of Federal Regulations)
• American Society of Plastic Surgeons: 2018 Plastic Surgery Statistics Report
• [National Conference of

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)